{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:48:57Z","timestamp":1649159337493},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10620-018-5334-7","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T10:12:16Z","timestamp":1539771136000},"page":"1432-1435","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TB or Not TB: Crohn\u2019s Disease, Peritoneal Tuberculosis, or Both?"],"prefix":"10.1007","volume":"64","author":[{"given":"Miquell","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim-Nhien","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Zemek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Kin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"5334_CR1","doi-asserted-by":"publisher","first-page":"e103303","DOI":"10.1371\/journal.pone.0103303","volume":"9","author":"J Du","year":"2014","unstructured":"Du J, Ma YY, Xiang H, Li YM. Confluent granulomas and ulcers lined by epithelioid histiocytes: new ideal method for differentiation of ITB and CD? A meta analysis. PLoS ONE. 2014;9:e103303.","journal-title":"PLoS ONE"},{"key":"5334_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/1751-2980.12324","volume":"17","author":"JY Ma","year":"2016","unstructured":"Ma JY, Tong JL, Ran ZH. Intestinal tuberculosis and Crohn\u2019s disease: challenging differential diagnosis. J Dig Dis. 2016;17:155\u2013161.","journal-title":"J Dig Dis"},{"key":"5334_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ajg.2016.529","volume":"112","author":"J Limsrivilai","year":"2017","unstructured":"Limsrivilai J, Shreiner AB, Pongpaibul A, et al. Meta-analytic Bayesian model for differentiating intestinal tuberculosis from Crohn\u2019s disease. Am J Gastroenterol. 2017;112:415\u2013427.","journal-title":"Am J Gastroenterol"},{"key":"5334_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10620-010-1399-7","volume":"56","author":"AT Ince","year":"2011","unstructured":"Ince AT, G\u00fcne\u015f P, Senate\u015f E, et al. Can an immunohistochemistry method differentiate intestinal tuberculosis from Crohn\u2019s disease in biopsy specimens? Dig Dis Sci. 2011;56:1165\u20131170. \n                    https:\/\/doi.org\/10.1007\/s10620-010-1399-7\n                    \n                  .","journal-title":"Dig Dis Sci"},{"key":"5334_CR5","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s10620-013-2667-0","volume":"58","author":"R Banerjee","year":"2013","unstructured":"Banerjee R, Balaji M, Sasikala M, et al. Granulomas of intestinal tuberculosis and Crohn\u2019s disease can be differentiated by CD73 cell surface marker expression: a pilot study. Dig Dis Sci. 2013;58:2301\u20132307. \n                    https:\/\/doi.org\/10.1007\/s10620-013-2667-0\n                    \n                  .","journal-title":"Dig Dis Sci"},{"key":"5334_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3748\/wjg.v16.i20.2496","volume":"16","author":"XJ Jin","year":"2010","unstructured":"Jin XJ, Kim JM, Kim HK, et al. Histopathology and TB-PCR kit analysis in differentiating the diagnosis of intestinal tuberculosis and Crohn\u2019s disease. World J Gastroenterol. 2010;16:2496\u20132503.","journal-title":"World J Gastroenterol"},{"key":"5334_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148\u2013155.","journal-title":"Lancet Infect Dis"},{"key":"5334_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.crohns.2012.02.018","volume":"6","author":"C Tissot","year":"2012","unstructured":"Tissot C, Couraud S, Meng L, et al. Life-threatening disseminated tuberculosis as a complication of treatment by infliximab for Crohn\u2019s disease: report of two cases, including cerebral tuberculomas and miliary tuberculosis. J Crohn\u2019s Colitis. 2012;6:946\u2013949.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5334_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2298\/SARH1108514M","volume":"139","author":"B Milenkovi\u0107","year":"2011","unstructured":"Milenkovi\u0107 B, Dudvarski-Ili\u0107 A, Jankovi\u0107 G, et al. Anti-TNF treatment and miliary tuberculosis in Crohn\u2019s disease. Srp Arh Celok Lek. 2011;139:514\u2013517.","journal-title":"Srp Arh Celok Lek"},{"key":"5334_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15585\/mmwr.mm6711a2","volume":"67","author":"RJ Stewart","year":"2018","unstructured":"Stewart RJ, Tsang CA, Pratt RH, Price SF, Langer AJ. Tuberculosis\u2014United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:317\u2013323. \n                    https:\/\/doi.org\/10.15585\/mmwr.mm6711a2\n                    \n                  .","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5334_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261\u20131265.","journal-title":"Clin Infect Dis"},{"key":"5334_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1128\/microbiolspec.tnmi7-0026-2016","volume-title":"Tuberculosis and Nontuberculous Mycobacterial Infections","author":"C Dobler","year":"2017","unstructured":"Dobler C. Biologic agents and tuberculosis. In: Schlossberg D, ed. Tuberculosis and Nontuberculous Mycobacterial Infections. 7th ed. Washington, DC: ASM Press; 2017:623\u2013635. \n                    https:\/\/doi.org\/10.1128\/microbiolspec.tnmi7-0026-2016\n                    \n                  .","edition":"7"},{"key":"5334_CR13","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884\u20131894.","journal-title":"Arthritis Rheum"},{"key":"5334_CR14","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/rheumatology\/keu041","volume":"53","author":"Y Kim","year":"2014","unstructured":"Kim Y, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014;53:1477\u20131481.","journal-title":"Rheumatology (Oxford)"},{"key":"5334_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40265-017-0765-6","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Duggan ST. Ustekinumab: a review in moderate to severe Crohn\u2019s disease. Drugs. 2017;77:1105\u20131114.","journal-title":"Drugs"},{"key":"5334_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/CEG.S110546","volume":"15","author":"A Jauregui-Amezaga","year":"2017","unstructured":"Jauregui-Amezaga A, Somers M, De Schepper H, Macken E. Next generation of biologics for the treatment of Crohn\u2019s disease: an evidence-based review on ustekinumab. Clin Exp Gastroenterol. 2017;15:293\u2013301.","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5334-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5334-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5334-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T23:18:56Z","timestamp":1571267936000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5334-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5334"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5334-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"17 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}